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Cucurbitacin I Inhibits Stat3 and Induces Apoptosis
in Se´zary Cells
Marloes S. van Kester1, Jacoba J. Out-Luiting1, Peter A. von dem Borne1,2, Rein Willemze1,
Cornelis P. Tensen1 and Maarten H. Vermeer1
Se´zary syndrome (Sz) is an aggressive cutaneous CD4þ T-cell lymphoma with tumor cells (Sz cells) localized in
the skin, lymph nodes, and peripheral blood. Using western blotting, we demonstrate the expression of
phosphorylated (P)-Stat3 in the Sz-derived cell line Seax, and in freshly isolated tumor cells from Sz patients
(n¼ 6). In Vitro overnight culture without exogenous cytokines results in decreased expression of P-Stat3
(n¼ 3), indicating that Stat3 is not constitutively activated. Incubation of the Seax cell line with the Jak/Stat3
inhibitor Cucurbitacin I resulted in a time- and concentration-dependent decrease of P-Stat3 and Stat3. In
freshly isolated Sz cells (n¼ 3), Cucurbitacin I induced a concentration-dependent decrease in Stat3 expression
whereas P-Stat3 was undetectable. Finally, incubation of freshly isolated Sz cells (n¼ 4) with 30 mM Cucurbitacin I
for 6 hours induced apoptosis in the large majority (73–91%) of tumor cells. These data strengthen the notion
that activation of Stat3 plays an essential part in the malignant transformation of Sz and provide further rationale
for the therapeutical targeting of Stat3 in Sz.
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INTRODUCTION
Se´zary syndrome (Sz) is an aggressive lymphoma/leukemia of
skin homing, CD4þ memory T cells characterized by the
presence of neoplastic T cells (Sz cells) in the skin, lymph
nodes, and peripheral blood. Patients present with pruritic
erythroderma and generalized lymphadenopathy. Ectropion,
alopecia, palmoplantar keratoderma, and generalized im-
munosuppression are common associated features (Willemze
et al., 2005). Although Sz can be treated with low dose
prednisone and chlorambucil or immunomodulating thera-
pies (extracorporeal photophoresis, IFN-a), the prognosis is
poor, with a median survival between 2 and 4 years after
diagnosis and a disease-specific 5-year survival around 20%.
The Stat proteins have dual roles as cytoplasmic signaling
proteins and nuclear transcription factors. Following activa-
tion by receptors with tyrosinase kinase activity, phospho-
rylated Stats dimerize and translocate to the nucleus to
induce expression of critical genes essential in normal
physiological cellular events. Persistent activation of Stats,
particularly Stat3, has been implicated in the pathogenesis of
a whole spectrum of malignancies, including T-cell lympho-
ma (Darnell Jr et al., 1994).
In Sz-derived cell lines as well as in Sz cells isolated from
peripheral blood, expression of phosphorylated (P)-Stat3 and
P-Stat5 has been reported. Recent studies have shown that in
Sz autocrine/paracrine signaling of IL-2, IL-7, and IL-15
cytokines results in phosphorylation of Stat3 and Stat5 (Foss
et al., 1994; Zhang et al., 1996; Eriksen et al., 2001; Qin
et al., 2001; Zhang et al., 2005). Therefore, activation of Stat3
and Stat5 through persistent cytokine signaling may play a
crucial role in the pathogenesis of Sz.
Recently, a new series of selective and potent Jak/Stat3
inhibitors was developed. Of these, Cucurbitacin I specifi-
cally decreased the levels of P-Stat3 in various human cancer
cell lines (Blaskovich et al., 2003; Sun et al., 2005; Shi et al.,
2006) and most importantly, inhibited tumor growth in mice
models (Blaskovich et al., 2003).
Based on these observations, inhibition of Stat3 signaling
is a promising therapeutic target in Sz but functional
experiments to validate this hypothesis have not been
performed thus far. The objectives of this study were (1) to
determine the expression of (P)-Stat3 in both freshly isolated
Sz cells and the Sz-derived Seax cell line, (2) to establish the
type of activation (constitutive vs non-constitutive), and (3)
to study the effects of the Stat3 inhibitor Cucurbitacin I on
(P)-Stat3 levels and the ability to trigger apoptosis in Sz cells.
RESULTS
Expression of activated Stat3(P-Stat3) by malignant cells in
patients with Sz
To determine the activation status of Stat3 by malignant cells
in Se´zary patients, 10 mg protein extracted by Trizol was
loaded on gel. As shown in Figure 1a, in all Sz patients both
expression of P-Stat3 and Stat3 was detected. In contrast, in
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peripheral blood mononuclear cells (PBMCs) from a healthy
control no expression of P-Stat3 and low levels of Stat3
were observed. In Vitro overnight culture without exogenous
cytokines resulted in decreased expression of P-Stat3 (n¼ 3),
whereas in the presence of exogenous cytokines P-stat3
expression increased or remained unaltered (Figure 1b).
Cucurbitacin I inhibits P-Stat3 and Stat3 in Seax cells
To determine whether Cucurbitacin I is capable of suppres-
sing Stat3 phosphorylation, time course experiments and
dose-escalating studies were performed using the Seax cell
line. Results from western blotting demonstrated that
Cucurbitacin I induced a dose-dependent decrease of both
P-Stat3 and Stat3 in Seax cells. In contrast, no decrease in
P-Stat3 or Stat3 expression was observed in negative controls
(Figure 2a).
Time course experiments demonstrated a time-dependent
decrease in expression for both P-Stat3 and Stat3 (Figure 2b).
This decrease in expression could already be detected after
1 hour of incubation. The decrease was more pronounced for
P-Stat3 than for the total amount of Stat3 protein. Again, no
decrease in expression of P-Stat3 or Stat3 expression was
observed in the negative control (Figure 2b).
Cucurbitacin I inhibits Stat3 in Se´zary cells
In a dose-escalating study, 3105 freshly isolated CD4þ
T cells from two Se´zary patients (Sz 2 and 5) were incubated
for 6 hours with various concentrations of Cucurbitacin I or
volume equivalents of DMSO as negative controls. After
incubation with Cucurbitacin I, cells were washed twice with
phosphate-buffered saline and subjected to lysis with lysis
buffer. A dose-dependent decrease in the total amount of
Stat3 (Figure 3a and b) was visible, while P-Stat3 was
undetectable in all samples tested (data not shown). To test
whether the absence of P-Stat3 was due to a limited amount
of protein, the number of Se´zary cells was increased to
5106 CD4þ in a follow-up experiment (Sz 6a) and the cells
were subjected to Trizol protein extraction. On each lane,
5 mg protein was loaded to normalize for the protein content.
However, P-Stat3 was still undetectable (data not shown),
whereas a similar dose-dependent decrease in total Stat3
level was observed (Figure 3c).
Cucurbitacin I-mediated inhibition of Stat3 induces apoptosis in
Se´zary cells
To examine whether apoptosis is induced in Se´zary cells by
inhibition of Stat3, freshly isolated CD4þ T cells (five
samples from four Se´zary patients Sz 2c, 5, 6a, 6b, and 7)
were incubated with 30 mM Cucurbitacin I for 6 hours. After
incubation with Cucurbitacin I, 73–91% apoptotic cells were
detected by flow cytometry analysis with Annexin-V and
propidium iodide staining (Figure 4). Incubation with
medium alone or medium containing volume equivalents of
DMSO resulted in a low percentage (5–19%) of apoptotic
cells. Incubation of freshly isolated CD4þ T cells from
healthy controls (n¼ 3) with Cucurbitacin I for 6 hours
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Figure 1. Stat3 is consistently expressed, but not constitutively activated in
patient-derived Sz cells. Western blot analysis of proteins isolated (Trizol
extraction) from 5106 PBMCs of six Sz patients (a) or CD4þ T cells (n¼ 3)
are cultured in the presence (c) and absence (s) of cytokines (10% T-cell
extract) for 17 hours (b) 10 mg protein was loaded on gel and subjected to
western blotting using P-Stat3 specific antibody. The blot was stripped and
reprobed with Stat3 antibody.
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Figure 2. Cucurbitacin I inhibits P-Stat3 and Stat3 expression in Seax cells in
a concentration- and time-dependent manner. (a) Cucurbitacin I (0.3, 1, 3,
10, and 30 mM), a volume equivalent of DMSO (solvent), or nothing was
added to 2105 Seax cells for 6 hours. In (b), 10 mM Cucurbitacin (1, 2, 4, or
6 hours), a volume equivalent of DMSO (6 hours), or nothing (6 hours) was
added. Cells were lysed with lysis buffer and 1/6 of the total cell lysate was
subjected to western blot analysis using specific antibody against P-Stat3. The
blot was stripped and reprobed with antibody against Stat3.
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resulted in apoptosis in 28% of the cells (mean, SEM 9.7%)
(Figure 4).
DISCUSSION
In this study, we show expression of P-Stat3 in Sz cells and
that inhibition of Stat3 by Cucurbitacin I results in decreased
expression of Stat3 and apoptosis of Sz cells.
Previous studies showed expression of P-Stat3 in Sz-
derived cell lines, whereas in freshly isolated Sz cells from
peripheral blood, P-Stat3 was detected in only 4 of 13
samples (Zhang et al., 1996). In this study, expression of
P-Stat3 was a consistent finding in all Sz patients tested. Also
in one patient in whom two samples taken with an interval of
14 months, expression of P-Stat3 was observed in both
samples. This difference in expression of P-Stat3 might result
from different clinical criteria used for patient selection or
differences in protein extraction and detection techniques.
In contrast to a former study performed in Seax cells
(Eriksen et al., 2001), Stat3 is not constitutively expressed in
primary patient material. After 8 hours, diminished expression
of (P)-Stat3 is visible in cells cultured in the absence of
exogenous cytokines compared to culture in the presence of
cytokines or immediately after isolation. These observations
suggest that paracrine cytokine stimulation is essential for
activation of Stat3.
The importance of the consistent expression of activated
Stat3 in Sz lies not only in a better understanding of the
pathogenesis of Sz but also in the validation of Stat3 as a
therapeutic target in the management of this disease. In this
study, we demonstrate a dose-dependent decrease in the
level of P-Stat3 expression using Cucurbitacin I. Of note, this
decrease in P-Stat3 levels was achieved in the presence of
crude T-cell factor, demonstrating that even in the presence
of cytokine stimulation, Cucurbitacin I can inhibit phospho-
rylation of Stat3 in Seax cells.
In contrast to previous studies on human tumor cell lines
(Blaskovich et al., 2003; Sun et al., 2005; Shi et al., 2006), we
observed a dose-dependent decrease in both P-Stat3 and
total amount of Stat3 protein after Cucurbitacin I treatment of
Seax cells.
Known targets of Stat3 are the antiapoptotic genes BCL-XL,
MCL1, and Survivin, and proliferation-inducing genes MYC
and cyclin D1 (Buettner et al., 2002). Previous studies in
ALKþ ALCL, lungadenocarcinoma and breast cancer cell
lines demonstrated that inhibition of P-Stat3 with Cucurbita-
cin I results in decreased expression of Stat3 target genes and
apoptosis of these cells (Blaskovich et al., 2003; Shi et al.,
2006). Moreover, using in vivo/murine models, Cucurbitacin
I has also been shown to have antitumor effects on various
types of tumors (Blaskovich et al., 2003). Our results
demonstrate that Cucurbitacin I induced a similar dose-
dependent decrease in the expression of Stat3 in freshly
isolated Sz cells as in Seax cells. In contrast, we could not
detect P-Stat3 in freshly isolated Sz cells, which may be
related to the sensitivity of the western blotting assay,
because in this particular experiment only 5 mg protein was
available, whereas for the other experiments 10 mg protein
could be used. We demonstrated that incubation of freshly
isolated Sz cells with 30 mM of Cucurbitacin I for 6 hours
induced apoptosis in 73–91% of Sz cells. Normal CD4þ
T cells showed a much lower sensitivity to Cucurbitacin
I-induced apoptosis supporting the potential of Stat3 inhibi-
tors as therapeutic agents in Sz.
In conclusion, we show consistent expression of P-Stat3 in
Sz cells and demonstrate that inhibition of Stat3 using
Cucurbitacin I results in apoptosis of these cells. Based on our
study, Stat3 inhibitors are a potential therapeutic agent for Sz.
MATERIALS AND METHODS
Cell lines
The Seax line (Kaltoft et al., 1987) was cultured in RPMI 1640 medium
supplemented with 20% fetal calf serum, 2mM L-glutamine, penicillin
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Figure 4. Apoptosis in CD4þ T cells of four different Sz patients and three
healthy donors. Sz cells and healthy CD4þ T cells were cultured with or
without 30mM Cucurbitacin I or with a volume equivalent of DMSO (solvent)
for 6 hours. Cells were subjected to propidium/Annexin V labeling and
apoptotic cells were quantified by FACS analysis. Healthy donors (indicated
with C): no addition 6 hours (mean 19%±SEM 3%), Cucurbitacin I 6 hours
(mean 28%±SEM 10%), DMSO 6hours (mean 19%±SEM 3%).
DMSO Cuc I
N
o addition
Control +
Control –
Cuc IDMSO
N
o addition
Control +
Control –
Cuc I
D
M
SO
N
o addition
Control +
Control –
Stat3
Stat3
Stat3
Sézary patient 5
Sézary patient 6
Sézary patient 2b
Figure 3. Cucurbitacin I decreases Stat3 expression in Se´zary cells. (a, b)
Cucurbitacin I (0.1, 0.3, 1, 3, 10, and 30mM), a volume equivalent of DMSO
(solvent), or nothing was added to 3105 CD4þ T cells for 6 hours. In
(c), Cucurbitacin I (0.3, 1, 10, and 30 mM) was added to 5106 CD4þ T cells
of a single Sz patient for 6 hours and a single DMSO control was used
(corresponding to the highest concentration inhibitor). (a, b) Cells were lysed
with lysis buffer or (c) protein was extracted with Trizol. (a, b) Cell lysates, 1/6
of total, or (c) 5 mg protein was analyzed by western blotting using antibody
against Stat3.
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100Uml1, streptomycin 100mgml1 (all from Invitrogen, Breda, the
Netherlands), and 10% T-cell extract (made from a buffy coat of a
healthy individual after stimulation with phytohaemagglutinin (PHA)
and IL-2).
Patients and healthy donors
Seven patients with Sz as defined by the World Health Organisation-
European Organization for Research and Treatment of Cancer
(WHO-EORTC) classification were selected for this study (Willemze
et al., 2005). In six patients, PBMCs were isolated at diagnosis by
Ficoll density centrifugation. In addition, in four of seven patients
(Sz 2, 5, 6, and 7), CD4þ T cells were isolated from PBMCs by
negative selection using magnetic beads (CD4þ T-cell isolation kit,
Miltenyi Biotec, Bergisch Gladbach, Germany). From one patient
(Sz 2), PBMCs were isolated both at diagnosis, after a 14-month
follow-up and after an 11-month follow-up, during which the patient
had been treated with low dose prednisone (10–40mg daily). From
another patient (Sz 6), CD4þ T cells were isolated at diagnosis and
after a 10-month follow-up, during which the patient had been
treated with 20–30mg prednisone and chlorambucil 2–4mg daily.
PBMCs isolated from a healthy donor served as normal control for
western blotting. For apoptosis assays, CD4þ T cells isolated from
healthy donors (n¼ 3) were used as normal controls. The freshly
isolated CD4þ T cells were maintained in RPMI 1640 medium
supplemented with 10% fetal calf serum, 2mM L-glutamine,
penicillin 100Uml1, and streptomycin 100mgml1 during the
Stat3 inhibition assays and the apoptosis assays. Approval for these
studies was obtained from the institutional review board of the
LUMC. Informed consent was provided according to the Declaration
of Helsinki Principles.
Cucurbitacin I
Cucurbitacin I (JSI-124) (National Cancer Institute NCI identifier:
NSC 521777), purchased from Indofine Chemical Company
(Hillsborough, NJ), was dissolved in DMSO to a concentration of
50mM. During the experiments, Cucurbitacin I was diluted in culture
medium to the final concentrations.
Stat3 activation assays
Protein from of 5 106 PBMCs (patient 1, 2a, 3, 2b, 4, 5, 6a) was
extracted using Trizol (Invitrogen) to determine the level of P-Stat3
and Stat3. To establish the type of activation, CD4þ T cells (patient
2c, 6b, and 7) were cultured in the presence and absence of 10%
T-cell extract for 17 hours. The protein concentration of the samples
was measured by a Nanodrop (ND-1000 Spectrophotomter,
PEQLAB Biotechnologie GMBH, Erlangen, Germany) and 10 mg of
protein was loaded on a 7% polyacrylamide gel.
Stat3 inhibition assays
In dose-escalating studies, 2 105 Seax or 3 105 Sz (patient 2b and
5) or 5 106 Sz (patient 6a) cells were treated with increasing
concentrations of Cucurbitacin I for 6 hours. The Seax or Se´zary cells
maintained in medium with an equivalent volume of DMSO
(solvent) added to the medium served as negative controls.
In time course experiments, Seax cells were maintained for
1–6 hours in 2ml medium containing 10 mM Cucurbitacin I. Seax
cells maintained in medium containing equivalent volume of DMSO
was used as control.
Cells from Cucurbitacin I inhibition assays (Seax and patients 2b
and 5) were washed twice with phosphate-buffered saline, lysed
with lysis buffer containing Tris-buffered saline-NP40 1%, 1:100
phosphatase inhibitor cocktail A (sc-45044, Santa Cruz Biotechno-
logies, Heidelberg, Germany), 1:100 phosphatase inhibitor cocktail B
(sc-45045, Santa Cruz Biotechnologies), and complete mini
Protease Inhibitor cocktail (Roche, Penzberg, Germany). One-sixth of
the lysate plus loading buffer was heated for 3minutes at 1001C,
spinned off and loaded on each lane of 7% polyacrylamide gel. The
protein content of the cells of patient 6 was extracted by means of Trizol
and measured by the Nanodrop, subsequently 5mg was electrophor-
esed.
Western blotting
Electrophoresed protein was transblotted to polyvinylidine difluoride
membranes (Amersham Biosciences, Buckinghamshire, England).
After transblotting, the polyvinylidine difluoride membranes were
blocked overnight at room temperature in 5% milk (Protifar plus,
Nutricia, Zoetermeer, the Netherlands) in Tris-buffered saline
containing 0.1% Tween 20. P-Stat3 and total Stat3 antibodies were
purchased from Cell Signaling Technologies (Danvers, MA). Goat
anti-rabbit IgG HRP was used as secondary antibody (Santa Cruz
Biotechnology). All antibodies were diluted in 5% milk in Tris-
buffered saline containing 0.1% Tween 20.
Chemilluminescence (West Femto Maximum Sensitivity Sub-
strate, Pierce, Rockford, IL) was used for visualization of the western
blots. All blot experiments were performed in duplo. After the initial
series of antibodies and substrates and recording on X-ray films,
blots were stripped (62.5mM Tris-HCl, pH 6.8, 2% SDS, 100mM
2-mercaptoethanol) and reciprocally reprobed with the other antibody.
Stat3 Control Cell Extracts (no. 9133) from Cell Signaling technology
were used as positive and negative controls.
Apoptosis assays
Based on the results of the experiments on Seax cells (Figure 2),
freshly isolated CD4þ T cells were incubated with 30 mM Cucurbi-
tacin I for 6 hours labeled with Annexin V and Propidium iodide
(Annexin-V-Fluos Staining kit, Roche) and analyzed by flow
cytometry using a Becton Dickenson FACS Scan. Results were
evaluated with Cell Quest software.
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